These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 37349949)
1. Mineral and bone metabolism markers and mortality in diabetic patients on haemodialysis. Martín-Carro B; Navarro-González JF; Ortiz A; Zoccali C; Floege J; Ferreira MA; Gorriz-Teruel JL; Carrillo-López N; Panizo S; Locatelli F; Ketteler M; London GM; Naves-Díaz M; Alonso-Montes C; Cannata-Andía JB; Fernández-Martín JL Nephrol Dial Transplant; 2023 Oct; 38(11):2589-2597. PubMed ID: 37349949 [TBL] [Abstract][Full Text] [Related]
2. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Fernández-Martín JL; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Gorriz JL; Rutkowski B; Ferreira A; Bos WJ; Covic A; Rodríguez-García M; Sánchez JE; Rodríguez-Puyol D; Cannata-Andia JB; Nephrol Dial Transplant; 2015 Sep; 30(9):1542-51. PubMed ID: 25920921 [TBL] [Abstract][Full Text] [Related]
3. Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients. Barrera-Baena P; Rodríguez-García M; Rodríguez-Rubio E; González-Llorente L; Ortiz A; Zoccali C; Locatelli F; Floege J; Cohen-Solal M; Ferreira MA; Ketteler M; London GM; Gorriz-Teruel JL; Sánchez-Álvarez E; Hevia-Suárez MÁ; Fernández-Gómez JM; Martín-Carro B; Gómez-Alonso C; Alonso-Montes C; Cannata-Andía JB; Fernández-Martín JL; Nephrol Dial Transplant; 2024 Mar; 39(4):618-626. PubMed ID: 37660283 [TBL] [Abstract][Full Text] [Related]
4. Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study. Neri L; Kreuzberg U; Bellocchio F; Brancaccio D; Barbieri C; Canaud B; Stuard S; Ketteler M Nephrol Dial Transplant; 2019 Apr; 34(4):682-691. PubMed ID: 30165528 [TBL] [Abstract][Full Text] [Related]
5. Association between CKD-MBD and mortality in older patients with advanced CKD-results from the EQUAL study. Magagnoli L; Cozzolino M; Caskey FJ; Evans M; Torino C; Porto G; Szymczak M; Krajewska M; Drechsler C; Stenvinkel P; Pippias M; Dekker FW; de Rooij ENM; Wanner C; Chesnaye NC; Jager KJ; Nephrol Dial Transplant; 2023 Oct; 38(11):2562-2575. PubMed ID: 37230954 [TBL] [Abstract][Full Text] [Related]
6. COSMOS: the dialysis scenario of CKD-MBD in Europe. Fernández-Martín JL; Carrero JJ; Benedik M; Bos WJ; Covic A; Ferreira A; Floege J; Goldsmith D; Gorriz JL; Ketteler M; Kramar R; Locatelli F; London G; Martin PY; Memmos D; Nagy J; Naves-Díaz M; Pavlovic D; Rodríguez-García M; Rutkowski B; Teplan V; Tielemans C; Verbeelen D; Wüthrich RP; Martínez-Camblor P; Cabezas-Rodriguez I; Sánchez-Alvarez JE; Cannata-Andia JB Nephrol Dial Transplant; 2013 Jul; 28(7):1922-35. PubMed ID: 23166310 [TBL] [Abstract][Full Text] [Related]
7. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients. Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436 [TBL] [Abstract][Full Text] [Related]
8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V; Torregrosa V Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742 [TBL] [Abstract][Full Text] [Related]
9. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987 [TBL] [Abstract][Full Text] [Related]
10. Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. Fernández-Martín JL; Dusso A; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Górriz JL; Rutkowski B; Bos WJ; Tielemans C; Martin PY; Wüthrich RP; Pavlovic D; Benedik M; Rodríguez-Puyol D; Carrero JJ; Zoccali C; Cannata-Andía JB; Nephrol Dial Transplant; 2019 Apr; 34(4):673-681. PubMed ID: 29741651 [TBL] [Abstract][Full Text] [Related]
11. Dietary interventions for mineral and bone disorder in people with chronic kidney disease. Liu Z; Su G; Guo X; Wu Y; Liu X; Zou C; Zhang L; Yang Q; Xu Y; Ma W Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010350. PubMed ID: 26376110 [TBL] [Abstract][Full Text] [Related]
12. Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012-2015). Al Salmi I; AlRukhaimi M; AlSahow A; Shaheen FA; Al-Ghamdi SM; AlAli F; AlGhareeb S; Al Maimani Y; AlGhonaim M; Bieber B; Tentori F; Pisoni RL; Saudi J Kidney Dis Transpl; 2016 Nov; 27(6 Suppl 1):62-80. PubMed ID: 27991480 [TBL] [Abstract][Full Text] [Related]
13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
14. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: effects on bone mineral metabolism. Collaborators of the Multicenter Study Group. Weinreich T; Ritz E; Passlick-Deetjen J Perit Dial Int; 1996; 16(3):260-8. PubMed ID: 8761540 [TBL] [Abstract][Full Text] [Related]
15. Phosphorus Consumption Within 1 Hour Prior to Blood Work and Associated Serum Levels of Phosphate, Calcium, and PTH in Adult Patients Receiving Hemodialysis Treatment. Mazzetti T; Hopman WM; Couture L; Christilaw E; Munroe J; Babiolakis CS; Adams MA; Holden RM Can J Kidney Health Dis; 2019; 6():2054358119856891. PubMed ID: 31285829 [TBL] [Abstract][Full Text] [Related]
16. Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study. Zhan Z; Smyth B; Toussaint ND; Gray NA; Zuo L; de Zoysa JR; Chan CT; Jin C; Scaria A; Hawley CM; Perkovic V; Jardine MJ; Zhang L BMC Nephrol; 2019 Jul; 20(1):258. PubMed ID: 31299919 [TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism. Soohoo M; Obi Y; Rivara MB; Adams SV; Lau WL; Rhee CM; Kovesdy CP; Kalantar-Zadeh K; Arah OA; Mehrotra R; Streja E Am J Nephrol; 2022; 53(2-3):157-168. PubMed ID: 35226895 [TBL] [Abstract][Full Text] [Related]
18. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Melamed ML; Eustace JA; Plantinga L; Jaar BG; Fink NE; Coresh J; Klag MJ; Powe NR Kidney Int; 2006 Jul; 70(2):351-7. PubMed ID: 16738536 [TBL] [Abstract][Full Text] [Related]
19. Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism. Costa AF; dos Reis LM; Ribeiro MC; Moysés RM; Jorgetti V Nephrol Dial Transplant; 2003 Apr; 18(4):743-9. PubMed ID: 12637644 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular mortality in peritoneal dialysis: the impact of mineral disorders. Truyts C; Custodio M; Pecoit-Filho R; Moraes TP; Jorgetti V J Bras Nefrol; 2021; 43(2):182-190. PubMed ID: 33576763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]